Welcome to our dedicated page for BECTON DICKINSON & CO SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BECTON DICKINSON & CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BECTON DICKINSON & CO's regulatory disclosures and financial reporting.
Becton Dickinson director Robert Luther Huffines acquired 189 rights to common stock under the BD Deferred Compensation Plan on 2026-08-06, credited at $165.62 per right. Each right converts into one share of common stock and is distributed after his board service ends or on dates he specifies. After this award, he directly holds 595 rights, including amounts accumulated through dividend investment.
Becton Dickinson director Carrie L. Byington received a grant of 94 rights to Common Stock under the BD Deferred Compensation Plan at a reference price of $165.62 per right. Each right converts one-for-one into Common Stock, bringing her total plan rights to 3,810, including rights added through dividend investment since her last report.
First Eagle Investment Management, LLC reports beneficial ownership of common stock of Becton Dickinson & Co. It is deemed to beneficially own 14,138,027 shares, representing 5.1% of the common stock. First Eagle has sole voting power over 12,845,517 shares and sole dispositive power over 14,138,027 shares.
The shares are held by or at the direction of First Eagle and/or its investment adviser subsidiaries, principally on behalf of investment advisory clients. Clients of First Eagle have the right to receive dividends and proceeds from any sale of these securities.
Becton, Dickinson and Company reported fiscal Q3 2026 revenue from continuing operations of $4,983 million, up 5.4% year over year, with GAAP diluted EPS from continuing operations of $1.64 and adjusted diluted EPS of $3.23, both increasing from the prior-year quarter.
Year-to-date, revenue reached $14,183 million, while net cash provided by continuing operating activities rose 33.3% to $2.1 billion and free cash flow grew 44.6% to $1.7 billion. Results reflect the February 9, 2026 spin-off of the Biosciences and Diagnostic Solutions business, now treated as discontinued operations.
The company updated its full-year fiscal 2026 outlook, targeting GAAP revenue growth in the low single-digit plus range and revenue growth (FXN) in the low single-digit range, and raised the midpoint of adjusted diluted EPS guidance to $12.62–$12.72 from a prior range of $12.52–$12.72.
Becton Dickinson & Co executive Michael Feld, EVP and Chief Revenue Officer, sold 75 shares of Common Stock on 2026-07-27 at $157.1300 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on February 7, 2025, and Feld now holds 20,934 shares directly.
BDX insider Michael Feld filed notice of a planned sale of common stock. The plan covers 75 shares, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an expected aggregate price of $11,727.00 on or after July 27, 2026 on the NYSE. The shares relate to Restricted Stock Units acquired from the issuer on August 20, 2025. The disclosure also lists prior sales under a Rule 10b5-1 trading plan: 75 shares for $11,460.00 on June 26, 2026 and 75 shares for $11,051.25 on May 26, 2026.
Becton, Dickinson and Company announced that Dr. Michael (Mike) Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments, plans to retire after more than 20 years with BD, effective October 2. He will remain in his role through the end of the fiscal year to support a smooth transition. A comprehensive search is underway to identify the next president of the Medical Essentials segment. To streamline the operating model, the BioPharma Systems segment will report directly to Chairman, CEO and President Thomas E. Polen, reflecting its strategic importance as a growth driver.
BD describes itself as one of the world’s largest pure-play medical technology companies, operating globally with more than 60,000 employees and delivering billions of products annually across medical essentials, connected care, biopharma systems and interventional therapies.
Becton Dickinson executive Muhsin Bilal reported routine equity compensation activity. He received 14,342 shares of Common Stock as a restricted stock unit award under the company’s 2004 equity-based compensation plan. In a separate entry, 1,935 shares were withheld to cover taxes upon RSU vesting. After these transactions, he directly holds 41,359 shares of Becton Dickinson common stock.